Last 36 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 101.05 | 53.29 | 44.58 | 57.29 | 42.21 | 30.08 | 50.48 | — | — | — | — | 12.53 | — | 16.76 | — | 59.92 | 1.01 | — | — | — | — |
| — | +77.2% | -11.7% | — | — | — | — | — | — | — | — | -79.1% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 8.52 | 5.47 | 4.63 | 4.03 | 4.19 | 3.44 | 3.07 | 2.92 | 3.99 | 3.05 | 4.36 | 3.82 | 4.55 | 3.53 | 3.88 | 4.32 | 2.28 | 6.22 | 5.34 | 10.83 | 16.17 |
| — | +59.2% | +50.9% | +38.1% | +4.9% | +12.7% | -29.7% | -23.6% | -12.2% | -13.5% | +12.4% | -11.5% | +99.0% | -43.3% | -27.3% | -60.1% | -85.9% | -79.9% | — | — | — | |
| P/B Ratio | 10.55 | 8.15 | 6.55 | 5.74 | 5.66 | 4.36 | 3.70 | 3.26 | 4.10 | 3.05 | 3.23 | 2.90 | 3.01 | 2.45 | 1.92 | 2.70 | 2.36 | 4.37 | 4.13 | 4.39 | 3.65 |
| — | +87.1% | +77.2% | +75.9% | +38.0% | +43.0% | +14.6% | +12.3% | +36.3% | +24.4% | +67.7% | +7.6% | +27.6% | -44.0% | -53.5% | -38.5% | -35.4% | +8.3% | -11.4% | +13.8% | +29.6% | |
| P/FCF | 227.28 | 28.49 | 19.83 | 15.29 | 22.95 | 19.31 | 19.02 | 19.25 | — | 64.13 | 89.26 | 74.63 | 17.96 | — | — | — | 3.65 | — | — | — | — |
| — | +47.6% | +4.2% | -20.6% | — | -69.9% | -78.7% | -74.2% | — | — | — | — | +391.9% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 71.34 | 46.69 | 31.84 | 38.32 | 29.35 | 24.06 | 28.35 | — | — | 988.65 | — | 929.62 | — | — | — | 33.40 | 3.89 | — | — | — | — |
| — | +94.1% | +12.3% | — | — | -97.6% | — | — | — | — | — | +2683.6% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 72.77 | 47.50 | 28.97 | 33.33 | 26.37 | 21.58 | 24.80 | — | — | 134.31 | — | 120.28 | — | — | — | 34.80 | 3.94 | — | — | — | — |
| — | +120.1% | +16.8% | — | — | -83.9% | — | — | — | — | — | +245.6% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.6% | 54.2% | 55.0% | 54.9% | 53.8% | 54.7% | 55.3% | 46.0% | 56.0% | 60.9% | 60.5% | 67.9% | 59.1% | 68.2% | 66.0% | 77.0% | 87.4% | 63.7% | 57.9% | 79.4% | 68.2% |
| — | -1.0% | -0.4% | +19.4% | -3.9% | -10.2% | -8.7% | -32.3% | -5.4% | -10.6% | -8.3% | -11.8% | -32.3% | +7.1% | +14.0% | -3.0% | +28.1% | +16.2% | — | — | — | |
| Operating Margin | 11.4% | 11.2% | 13.7% | 9.8% | 13.3% | 12.9% | 9.6% | -15.7% | -8.6% | -0.1% | -20.7% | 0.1% | -16.3% | -4.4% | -23.2% | 9.8% | 46.8% | -71.8% | -72.4% | -192.8% | -253.6% |
| — | -13.2% | +41.8% | +162.1% | +254.3% | +12038.2% | +146.5% | -16320.1% | +47.2% | +97.6% | +10.6% | -99.0% | -134.8% | +93.9% | +68.0% | +105.1% | +118.5% | +86.4% | — | — | — | |
| Net Margin | 8.7% | 10.4% | 10.5% | 7.0% | 10.2% | 11.4% | 6.2% | -7.3% | -11.3% | -3.6% | -22.2% | 30.3% | -20.7% | 20.9% | -25.4% | 7.2% | 226.0% | -74.1% | -78.3% | -193.8% | -252.5% |
| — | -8.2% | +70.1% | +196.8% | +190.1% | +416.1% | +128.0% | -124.0% | +45.3% | -117.2% | +12.7% | +319.8% | -109.1% | +128.3% | +67.6% | +103.7% | +189.5% | +86.3% | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.7% | 4.0% | 3.9% | 2.6% | 3.6% | 3.7% | 1.9% | -2.0% | -2.9% | -0.9% | -4.1% | 6.0% | -3.4% | 3.7% | -3.1% | 1.1% | 83.4% | -12.5% | -14.4% | -18.2% | -13.6% |
| — | +7.8% | +102.0% | +226.8% | +222.9% | +515.3% | +146.9% | -134.0% | +14.2% | -124.1% | -30.3% | +423.0% | -104.1% | +129.9% | +78.3% | +106.3% | +714.0% | +23.8% | +15.5% | -13.8% | +5.7% | |
| ROA | 8.8% | 3.0% | 2.8% | 1.9% | 2.7% | 2.8% | 1.4% | -1.6% | -2.3% | -0.7% | -3.4% | 5.0% | -2.9% | 3.2% | -2.7% | 1.0% | 66.8% | -9.1% | -10.9% | -15.0% | -11.5% |
| — | +4.4% | +96.5% | +222.9% | +216.1% | +484.5% | +142.8% | -131.3% | +19.3% | -122.8% | -24.5% | +415.4% | -104.3% | +135.7% | +75.0% | +106.5% | +682.2% | +35.7% | +27.4% | -2.3% | +14.1% | |
| ROIC | 17.1% | 4.5% | 5.2% | 3.8% | 5.3% | 4.9% | 3.5% | -4.7% | -2.1% | -0.0% | -3.8% | 0.0% | -2.7% | -0.8% | -2.8% | 1.8% | 25.0% | -16.9% | -19.8% | -54.6% | -44.0% |
| — | -7.9% | +51.6% | +180.6% | +354.0% | +18077.4% | +190.2% | -25007.9% | +22.3% | +96.4% | -35.9% | -99.0% | -110.7% | +95.5% | +85.7% | +103.4% | +156.8% | +35.8% | +3.1% | -229.8% | -173.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 |
| — | -31.1% | -31.3% | -25.6% | -25.1% | -24.7% | -22.9% | -19.5% | -24.2% | -20.2% | +95.3% | +87.0% | +83.2% | +9.3% | -55.7% | -54.3% | -44.6% | +15.5% | +33.9% | +46.0% | +630.3% | |
| Debt / EBITDA | 0.12 | 0.32 | 0.30 | 0.47 | 0.40 | 0.48 | 0.73 | — | — | 36.43 | — | 38.67 | — | — | — | 0.83 | 0.14 | — | — | — | — |
| — | -32.4% | -58.3% | — | — | -98.7% | — | — | — | — | — | +4557.4% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.79 | 3.90 | 3.79 | 3.79 | 3.85 | 3.57 | 3.66 | 3.30 | 3.24 | 3.57 | 4.21 | 4.34 | 4.79 | 5.18 | 6.33 | 5.16 | 4.28 | 4.13 | 3.95 | 4.38 | 6.32 |
| — | +9.5% | +3.7% | +14.9% | +18.6% | -0.1% | -13.2% | -24.0% | -32.3% | -31.1% | -33.4% | -16.0% | +11.9% | +25.4% | +60.3% | +17.8% | -32.2% | -34.5% | -49.2% | -58.1% | -58.4% | |
| Quick Ratio | 3.39 | 3.49 | 3.33 | 3.39 | 3.51 | 3.16 | 3.43 | 3.04 | 2.95 | 3.16 | 3.79 | 3.85 | 4.31 | 4.68 | 5.69 | 4.71 | 4.02 | 3.67 | 3.68 | 4.30 | 6.16 |
| — | +10.5% | -3.1% | +11.8% | +19.3% | +0.0% | -9.4% | -21.2% | -31.7% | -32.5% | -33.4% | -18.2% | +7.2% | +27.3% | +54.3% | +9.4% | -34.7% | -40.2% | -52.2% | -58.9% | -59.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | 1.34 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KNSA stock.
Kiniksa Pharmaceuticals International, plc's current P/E is 101.1x. The average P/E over the last 4 quarters is 49.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kiniksa Pharmaceuticals International, plc's current operating margin is 11.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kiniksa Pharmaceuticals International, plc's business trajectory between earnings reports.